Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 27:2022:2229735.
doi: 10.1155/2022/2229735. eCollection 2022.

Safety and Effectiveness of Inhaling Different Dosage Recombinant Human Interferon α 1B for Bronchiolitis in Children: a Systematic Review and Meta-Analysis

Jiefeng Luo  1   2   3   4 , Mengting Yang  2   3   4   5 , Linan Zeng  2   3   4 , Xiangcheng Pan  1   2   3   4 , Dan Liu  1   2   3   4 , Sha Diao  2   3   4 , Liang Huang  2   3   4 , Ting Chen  6 , Zhi-Jun Jia  1   2   3   4 , Guo Cheng  4   6   7 , Qin Yu  4   8 , Lingli Zhang  2   3   4
Affiliations

Safety and Effectiveness of Inhaling Different Dosage Recombinant Human Interferon α 1B for Bronchiolitis in Children: a Systematic Review and Meta-Analysis

Jiefeng Luo et al. Evid Based Complement Alternat Med. .

Abstract

Purpose: To systematically evaluate the safety and effectiveness of different dosages of recombinant human interferon α1b (IFNα1b) inhaled for bronchiolitis in children.

Methods: 7 databases, including PubMed, EMBASE, Cochrane Library, Web of Science, CNKI, Wanfang Database, and VIP, were searched. The search time was from their inception dates to March 28, 2022. A randomized controlled trial (RCT) of 2 μg/kg IFNα1b (low dosage group) monotherapy or in combination with other drugs vs. 4 μg/kg IFNα1b (high dosage group) monotherapy or in combination with the other drugs was included. The risk of bias 2.0 evaluated the RCT's quality, and the grading of recommendations assessment, development and evaluation (GRADE) tool was used for evaluating the overall quality of the evidence. Then, a meta-analysis was performed by RevMan 5.4.

Results: A total of 13 RCTs with 1719 children were included. The meta-analysis results showed that the high dosage group was significantly shorter than the low dosage group of the duration of hospital stays (MD = -0.40, 95%CI (-0.73, -0.07), P = 0.02) (low quality), three depressions sign disappearing time (MD = -0.60, 95%CI (-1.05, -0.14), P = 0.010) (low quality), and wheeze disappearing time (MD = -0.62, 95%CI (-1.17, -0.06), = 0.03) (low quality). There was no significant difference between the two groups in coughing disappearing time, pulmonary rales disappearing time, wheezing sound disappearing time, or adverse event rates.

Conclusions: Compared with low dosage IFNα1b, high dosage IFNα1b reduces the duration of hospital stays, the disappearance time of the three depression signs, and the disappearance time of wheeze in the treatment of bronchiolitis in children. Limited by the low quality of the evidence, the conclusions still need to be supported by high-quality studies.

PubMed Disclaimer

Conflict of interest statement

The author reports no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Literature screening flow diagram.
Figure 2
Figure 2
Risk of bias summary.
Figure 3
Figure 3
Risk of bias graph.
Figure 4
Figure 4
The duration of hospital stays.
Figure 5
Figure 5
Three depression signs disappearing time.
Figure 6
Figure 6
Coughing disappearing time.
Figure 7
Figure 7
Pulmonary rales disappearing time.
Figure 8
Figure 8
Wheeze disappearing time.
Figure 9
Figure 9
Wheezing sound disappearing time.
Figure 10
Figure 10
Adverse event rates (RRs).
Figure 11
Figure 11
Adverse event rates (RDs).
Figure 12
Figure 12
Subgroup analysis (the duration of hospital stays).
Figure 13
Figure 13
Subgroup analysis (adverse event rates (RRs)).
Figure 14
Figure 14
Subgroup analysis (adverse event rates (RDs)).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Merck Clinic Manual[homepage on the Internet]. Bronchiolitis. 2018-08-01; https://www.msdmanuals.cn/professional/pediatrics/respiratory-disorders-....
    1. Florin T. A., Plint A. C., Zorc J. J. Viral bronchiolitis. The Lancet . 2017;389(10065):211–224. doi: 10.1016/S0140-6736(16)30951-5. - DOI - PMC - PubMed
    1. Liu E., Chen H., Qian Y. Expert consensus on the diagnosis, treatment and prevention of bronchiolitis (2014) Chin J Pediatr . 2015;53(03):168–171. - PubMed
    1. Meyburg J., Ries M. Decision-making in acute viral bronchiolitis: a universal guideline and a publication gap. PLoS One . 2020;15(8):p. e0237801. doi: 10.1371/journal.pone.0237801. - DOI - PMC - PubMed
    1. Chen L., Shi M., Deng Q. αA multi-center randomized prospective study on the treatment of infant bronchiolitis with interferon α1b nebulization. PLoS One . 2020;15(2):p. e0228391. doi: 10.1371/journal.pone.0228391. - DOI - PMC - PubMed

LinkOut - more resources